Exclusive: After winning legal battle, former PhaseBio investor finds US buyer for its PhIII drug to reverse Brilinta

11 May 2023

Patent InfringementAcquisitionLicense out/inPriority Review

Having wrangled control of a blood thinner reversal agent, SFJ Pharma has found a buyer for the drug. SERB Pharmaceuticals, a specialty pharma that vastly expanded its portfolio through several mergers in recent years, is picking up US rights to bentracimab, which is designed to reverse the anti-coagulating effects of AstraZeneca’s Brilinta (ticagrelor). PhaseBio originally licensed the drug from AstraZeneca’s former biologics arm MedImmune, and SFJ hopped aboard midway with development funding. But when PhaseBio sounded an alarm bell regarding the company’s finances, SFJ demanded rights to the drug — and won the legal battle earlier this year. In the process, PhaseBio also filed for Chapter 11 bankruptcy .

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

PhaseBio Pharmaceuticals, Inc.SFJ Pharma Ltd. II

SERB

[+1]

Indications

Targets

Drugs

TicagrelorBentracimab

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.